Teva Pharmaceutical Industries (TEVA) Other Operating Expenses (2017 - 2026)

Teva Pharmaceutical Industries has disclosed Other Operating Expenses across 10 years of filings, most recently posting $9.0 million for Q1 2026.

• Quarterly Other Operating Expenses rose 280.0% year-over-year to $9.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$5.0 million (down 150.0% YoY) and the FY2025 annual result came in at -$18.0 million, down 228.57% from the prior year.
• Other Operating Expenses improved to $9.0 million in Q1 2026, from -$3.0 million in the prior quarter.
• Over five years, Other Operating Expenses peaked at $52.0 million in Q1 2022 and troughed at -$8.0 million in Q4 2024.
• A 5-year average of $9.5 million and a median of $2.0 million in 2022 frame the typical range for Other Operating Expenses.
• Annual changes were most pronounced in 2022 — Other Operating Expenses surged 940.0% — and 2025, when it tumbled 400.0%.
• Tracing TEVA's Other Operating Expenses over 5 years: stood at $19.0 million in 2022, then sank by 68.42% to $6.0 million in 2023, then plunged by 233.33% to -$8.0 million in 2024, then soared by 62.5% to -$3.0 million in 2025, then surged by 400.0% to $9.0 million in 2026.
• Business Quant data shows TEVA's Other Operating Expenses at $9.0 million in Q1 2026, -$3.0 million in Q4 2025, and -$7.0 million in Q3 2025.